ARA-290

ARA-290

Across all neuropathy trials, ARA-290 consistently had these benefits:

1. Symptom relief - less burning, tingling, and pain.

2. Objective repair - actual regrowth of damaged small nerve fibers seen under the microscope

In patients with diabetes, ARA-290 also improved metabolic markers such as glucose and triglycerides, likely by reducing inflammation at the cellular level.

Based on the data, the people most likely to benefit from ARA-290 are:

• Patients with sarcoidosis and small-fiber neuropathy, especially those with confirmed nerve fiber loss and significant pain.

• People with type 2 diabetes and painful neuropathy, particularly in early stages when there is still nerve tissue left to repair.

• Anyone with documented small-fiber damage on skin biopsy or corneal imaging and an inflammatory component to their condition.

Dosage: All human trials used subcutaneous injections. The effective dose was 4 mg once daily.  Lower doses, like 1 or 2 mg saw minor improvement, and higher doses up to 8 mg did not improve results further than 4mg.

1.6 cc BAC in 16mg vial = 1mg per 10 units.  Typical dose would then be 40 units daily, and the vial would last 4 days.